Mass balance and metabolism of aclidinium bromide following intravenous administration of [ 14C]-aclidinium bromide in healthy subjects

Biopharmaceutics and Drug Disposition

Volumn 33, Issue 1, 2012, Pages 39-45

  Ortiz, Stephan ^a   Flach, Stephen ^b   Ho, John ^a   Li, Fanying ^a   Caracta, Cynthia F ^a   Garcia Gil, Esther ^c   Jansat, Josep M ^c  

^a FOREST RESEARCH INSTITUTE   (United States)

^b 206 Carnegie Center   (United States)

^c Almirall ^*  (Spain)

Author keywords

Aclidinium bromide; COPD; Mass balance; Metabolism; Pharmacokinetics

Indexed keywords

ACLIDINIUM BROMIDE; ALCOHOL; CARBON 14; DRUG METABOLITE;

ADULT; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG EXCRETION; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FECES ANALYSIS; HUMAN; HUMAN EXPERIMENT; INJECTION SITE REACTION; MALE; NORMAL HUMAN; OPEN STUDY; PAIN; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT; URINALYSIS;

ADULT; FECES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MUSCARINIC ANTAGONISTS; TROPANES; YOUNG ADULT;

EID: 84857992916     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.1773     Document Type: Article

References (14)

1. Gross NJ, Co E, Skorodin MS. Cholinergic bronchomotor tone in COPD. Estimates of its amount in comparison with that in normal subjects. Chest 1989; 96: 984-987. (Pubitemid 19266543)
2. Kesten S, Jara M, Wentworth C, Lanes S. Pooled clinical trial analysis of tiotropium safety. Chest 2006; 130: 1695-1703. (Pubitemid 46033421)
3. Spiriva® HandiHaler® (tiotropium bromide inhalation powder) [package insert] Ridgefield, CT, Boehringer Ingelheim International GmbH, 2010.
4. Gavalda A, Miralpeix M, Ramos I, et al. Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile. J Pharmacol Exp Ther 2009; 331: 740-751.
5. Prat M, Fernandez D, Buil MA, et al. Discovery of novel quaternary ammonium derivatives of (3R)- quinuclidinol esters as potent and long-acting muscarinic antagonists with potential for minimal systemic exposure after inhaled administration: identification of (3R)-3-{[hydroxy(di-2-thienyl)acetyl] oxy}-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide (aclidinium bromide). J Med Chem 2009; 52: 5076-5092.
6. Sentellas S, Ramos I, Alberti J, et al. Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolites. Eur J Pharm Sci 2010; 39: 283-290.
7. Alberti J, Martinet A, Sentellas S, Salva M. Identification of the human enzymes responsible for the enzymatic hydrolysis of aclidinium bromide. Drug Metab Dispos 2010; 38: 1202-1210.
8. Jansat JM, Lamarca R, Garcia Gil E, Ferrer P. Safety and pharmacokinetics of single doses of aclidinium bromide, a novel long-acting, inhaled antimuscarinic, in healthy subjects. Int J Clin Pharmacol Ther 2009; 47: 460-468.
9. Ortiz S, Flach S, Caracta C, Garcia Gil E, Jansat JM. Safety and tolerability of aclidinium administered intravenously and absolute bioavailability of inhaled aclidinium in healthy male participants [published online ahead of print May 31, 2011]. J Clin Pharmacol 2011. doi:10.1177/ 0091270011406281.
10. Newman SP, Sutton DJ, Segarra R, Lamarca R, de Miquel G. Lung deposition of aclidinium bromide from Genuair, a multidose dry powder inhaler. Respiration 2009; 78: 322-328.
11. Cereda E, Ezhaya A, Gil Quintero M, et al. Synthesis and biological evaluation of new antimuscarinic compounds with amidine basic centers. A useful bioisosteric replacement of classical cationic heads. J Med Chem 1990; 33: 2108-2113. (Pubitemid 20236652)
12. Jansat JM, Lamarca R, de Miquel G, Schrodter A, Miletzki B, Gurniak M. Safety and pharmacokinetics of multiple doses of aclidinium bromide, a novel long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease, in healthy participants. J Clin Pharmacol 2009; 49: 1239-1246.
13. Schmid K, Pascual S, Garcia Gil E, Ortiz S, Jansat JM. Pharmacokinetics and safety of aclidinium bromide, a muscarinic antagonist, in adults with normal or impaired renal function: A phase I, open-label, single- dose clinical trial. Clin Ther 2010; 32: 1798-1812.
14. Alberti JJ, Sentellas S, Salva M. In vitro liver metabolism of aclidinium bromide in preclinical animal species and humans: identification of the human enzymes involved in its oxidative metabolism. Biochem Pharmacol 2011; 81: 761-776.